Idec Zevalin Clears Cmte.: Non-Refractory Use May Be Accelerated Approval
Executive Summary
FDA should consider approving Idec's Zevalin for use in lymphoma patients who have not failed Rituxan therapy under the accelerated approval regulations, FDA's Oncologic Drugs Advisory Committee said Sept. 11.
You may also be interested in...
From Avastin To Zevalin: ODAC’s Most Memorable Moments
The current and former leaders of FDA’s Oncologic Drugs Advisory Committee recount their most memorable moments of service on the panel.
Corixa/GSK Will Submit Bexxar-Zevalin Trial Protocol To FDA In January
Corixa and GlaxoSmithKline will conduct a head-to-head study of their non-Hodgkin's lymphoma treatment Bexxar and Idec's Zevalin, Corixa told FDA's Oncologic Drugs Advisory Committee Dec. 17
Corixa/GSK Will Submit Bexxar-Zevalin Trial Protocol To FDA In January
Corixa and GlaxoSmithKline will conduct a head-to-head study of their non-Hodgkin's lymphoma treatment Bexxar and Idec's Zevalin, Corixa told FDA's Oncologic Drugs Advisory Committee Dec. 17